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Key PointsPresence of interictal epileptiform discharges had the greatest predictive value in determining risk for developing seizures in infants with tuberous sclerosis complex TSCRoutine awake and sleep video--electroencephalography (EEG) can be used as a biomarker for ongoing epileptogenesis in the majority of infants with TSCThis study demonstrates that the decline in developmental outcome in infants with TSC is clearly linked to the persistence of seizures

1. INTRODUCTION {#epi16379-sec-0006}
===============

Tuberous sclerosis complex (TSC) is an autosomal dominant genetic disorder that affects approximately one in 6000 individuals due to mutations in the *TSC1* or *TSC2* genes.[1](#epi16379-bib-0001){ref-type="ref"}, [2](#epi16379-bib-0002){ref-type="ref"}, [3](#epi16379-bib-0003){ref-type="ref"} Epilepsy affects about 80% of individuals with TSC,[4](#epi16379-bib-0004){ref-type="ref"} mostly starting in the first 2 years of life. Approximately 65% of those with epilepsy have medically refractory epilepsy, which increases the likelihood of comorbid developmental delay and autism.[4](#epi16379-bib-0004){ref-type="ref"}

Increasingly, TSC is diagnosed at a young age before the onset of epilepsy from non‐neurologic findings, such as cardiac rhabdomyomas.[5](#epi16379-bib-0005){ref-type="ref"} Thus, TSC is an ideal disease model for prospectively studying epileptogenesis, well before the first clinical seizure onset. This concept provides an opportunity to implement potential antiepileptogenic therapy in infants to prevent epilepsy, and potentially positively influence developmental outcomes.

In a smaller open‐label study, vigabatrin initiation upon electroencephalography (EEG) abnormalities, but prior to the onset of epilepsy, improved eventual epilepsy and developmental outcomes in children with TSC, as compared to the standard of care of treating seizures when they occur.[6](#epi16379-bib-0006){ref-type="ref"} We previously described a subset of the patients in this study and showed feasibility of enrolling TSC infants prior to epilepsy onset and the use of serial EEG as a feasible strategy to identify TSC infants at risk for epilepsy in those monitored at minimum until 12 months of age.[7](#epi16379-bib-0007){ref-type="ref"} Here we describe the cohort's clinical and developmental outcomes at 24 months of age.

2. MATERIALS AND METHODS {#epi16379-sec-0007}
========================

2.1. Study design and participant recruitment {#epi16379-sec-0008}
---------------------------------------------

This longitudinal cohort study enrolled participants across five TSC centers: University of Alabama at Birmingham, University of California Los Angeles, Boston Children\'s Hospital, Cincinnati Children\'s Hospital Medical Center, and University of Texas Health Science Center at Houston. All five sites recruited from their respective TSC clinics, with each site\'s principal investigator also being the TSC clinic director for that site. Each site\'s principal investigator reached out to his/her local and regional networks of physicians, including geneticists, pediatric cardiologists, and maternal fetal medicine specialists. In addition, the Tuberous Sclerosis Alliance helped recruit nationally by advertising the study. Enrollment goal was 40 infants, and inclusionary/exclusionary criteria as well as visit time points and testing modalities are summarized in Table [1](#epi16379-tbl-0001){ref-type="table"}. Participants referred for this initial screening and enrollment were seen within 2 weeks. As part of our research protocol, to help parents identify seizures, a seizure recognition educational video was shown to the parents at the time of enrollment. Enrolled participants were followed until the age of 24 months. Linear mixed models were used to evaluate longitudinal outcomes. These models included categorizations of participants repeated measures (ie, 6, 12, 24 months), and their interactions as fixed effects with no other covariates included.

###### 

Study protocol and design

  Study inclusion criteria (meet all 3)                                                                                                                     Study exclusion criteria (meet any 1)
  --------------------------------------------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Meets genetic or clinical diagnostic criteria for TSC1/2 citation7 mo of age or younger at the time of enrollmentSeizure‐free at the time of enrollment   Gestational age \<30 wk at time of deliveryTaking vigabatrin or mammalian target of rapamycin (mTOR) inhibitor prior to or at time of enrollmentHistory of central nervous system infection, hypoxicIschemic encephalopathy, intraventricular hemorrhage, history of clinical seizures, including infantile

  Tests                                                          Age in months                               
  -------------------------------------------------------------- --------------- --- --- --- --- --- --- --- ---
  History/exam[a](#epi16379-note-0001){ref-type="fn"}            X               x   x   X   x   X   x   x   x
  Video‐EEG[b](#epi16379-note-0002){ref-type="fn"}               X               x   x   X   x   X   x   x   x
  Developmental Testing[c](#epi16379-note-0003){ref-type="fn"}                               x       x       x

First visit: demographics, medical history including seizures, medications, family history, physical/neurologic exam; at subsequent visits: seizure types and frequency, interval medical history, medications, physical/neurologic exam.

Standardized protocol across all five sites, 1‐h awake and asleep video‐EEG, 2000 Hz sampling rate.

Mullen and Vineland II.
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The study protocol was approved by the institutional review board at each site, with direction from the leading administrative site at the University of Alabama at Birmingham. Written informed consent was obtained from the parents or legal guardians of all participants. The trial was conducted in accordance with Good Clinical Practice guidelines. Data from each study site were entered into a web‐based, distributed data‐management system meeting HIPAA privacy regulations.

2.2. Video‐EEG recording and interpretation {#epi16379-sec-0009}
-------------------------------------------

A 1‐hour awake and asleep video‐EEG acquisition protocol was standardized across all five sites, with 2000 Hz sampling rate, 500 Hz high‐frequency filter, no low‐frequency filter (although default low‐frequency filter settings ranged between 0 and 0.05 Hz among the various EEG manufacturers), and 24 electrodes including ground and reference. EEG studies were performed at the baseline enrollment study visit and then every 6 weeks until the participant was 6 months of age, then every 3 months until 12 months of age, and then every 6 months until 24 months of age. Each video‐EEG was interpreted locally at each site to ensure that families were notified of all ictal events in a timely manner. Each EEG was deidentified and uploaded to a secure server at the UCLA site, and independently interpreted by two board‐certified pediatric electroencephalographers (M.G. and J.M.P.) with the National Institutes of Health/National Institute of Neurological Disorders and Stroke (NIH/NINDS) Scalp EEG Common Data Elements form. Should any of the five major categories differ between the two central readers---namely, the presence or absence of interictal epileptiform discharges (IEDs), hypsarrhythmia, ictal events, generalized or focal slowing, and generalized or focal attenuation---a third board‐certified pediatric electroencephalographer (J.Y.W.) adjudicated the item(s) in dispute. Except for age, necessary for appropriate pediatric EEG interpretation, all three readers were blinded to the participant\'s clinical history, including epilepsy onset, seizure type, and anticonvulsant treatment. The consensus between the two central readers, or the adjudicated results, was then the final EEG interpretation for analysis.

If the infant at any point in the study developed clinical or electrographic seizures, additional medical history and EEG or video‐EEG of varying duration were completed for clinical purposes at the discretion of the treating neurologist, as well as the choice and dosing of anticonvulsant drug initiation. This clinical information was recorded, as were all medical therapies throughout the duration of the study. The research video‐EEG studies continued to be collected at the designated time points as outlined in the protocol, even after clinical seizure onset.

2.3. Developmental testing {#epi16379-sec-0010}
--------------------------

Developmental assessments with Mullen Scales of Early Learning[8](#epi16379-bib-0008){ref-type="ref"} and Vineland Adaptive Behavior Scales, Second Edition (Vineland‐II)[9](#epi16379-bib-0009){ref-type="ref"} were obtained at 6, 12, and 24 months by research‐certified pediatric psychologists at each of the five participating sites. The Mullen Scales of Early Learning, a well‐validated and widely used measure to assess developmental status in infants and preschoolers was chosen to assess overall development. The Mullen includes scales measuring fine and gross motor skills, expressive and receptive language skills, and visual reception. The Vineland‐II was used to evaluate each child for the presence of adaptive functional delays, that is, delays in everyday living skills in the areas of communication, daily living skills, socialization, and fine and gross motor function.

2.4. Data analysis {#epi16379-sec-0011}
------------------

Categorical outcomes, which were summarized by percentage and between‐group differences, were evaluated with chi‐square tests. Continuous outcomes were summarized by means, medians, standard deviations, and ranges; between‐group differences were evaluation with analysis of variance (ANOVA) models. Linear mixed models were used to evaluate longitudinal outcomes. All analyses were performed in SAS version 9.4.

2.5. Data availability {#epi16379-sec-0012}
----------------------

The deidentified data for this study are retained with the Data Coordinating Center at the University of Alabama at Birmingham. The data as well as the study protocol and statistical analysis will be shared upon request. A formal request through the TSC‐Clinical Research Consortium (TSC‐CRC) is required to access data, and a formal project proposal should be submitted before the data will be released. The primary contact for data access is through the TSC‐CRC project manager at Boston Children\'s Hospital.

3. RESULTS {#epi16379-sec-0013}
==========

3.1. Cohort characteristics {#epi16379-sec-0014}
---------------------------

A total of 40 participants enrolled in the study over approximately 17 months from February 2013 to June 2014. Their demographic, genetic, and pertinent EEG and seizure information are summarized in Table [2](#epi16379-tbl-0002){ref-type="table"}.

###### 

Demographics per participant

  Participant                                 Race[a](#epi16379-note-0004){ref-type="fn"}   Gender[b](#epi16379-note-0005){ref-type="fn"}   Genetic testing[c](#epi16379-note-0006){ref-type="fn"}, [d](#epi16379-note-0007){ref-type="fn"}   Age enrolled (mo)   Age first EEG abnormal (mo)   Type of EEG spike   Age at clinical Sz onset (mo)   Clinical Sz type[c](#epi16379-note-0006){ref-type="fn"}, [d](#epi16379-note-0007){ref-type="fn"}
  ------------------------------------------- --------------------------------------------- ----------------------------------------------- ------------------------------------------------------------------------------------------------- ------------------- ----------------------------- ------------------- ------------------------------- --------------------------------------------------------------------------------------------------
  1                                           C                                             M                                               *TSC1*                                                                                            4.6                 NA                            NA                  NA                              NA
  2                                           C                                             F                                               *TSC1*                                                                                            7.1                 NA                            NA                  NA                              NA
  3                                           C                                             M                                               *TSC2*                                                                                            1.4                 9.6                           Focal               NA                              NA
  4                                           C                                             M                                               *TSC2*                                                                                            2.1                 NA                            NA                  NA                              NA
  5                                           C                                             F                                               *TSC1*                                                                                            7.3                 NA                            NA                  NA                              NA
  6                                           C                                             M                                               *TSC1*                                                                                            0.4                 NA                            NA                  NA                              NA
  7[e](#epi16379-note-0008){ref-type="fn"}    C                                             F                                               *TSC2*                                                                                            2.7                 2.7                           Regional            NA                              NA
  8                                           C                                             M                                               ND                                                                                                2.1                 NA                            NA                  NA                              NA
  9                                           C                                             M                                               *TSC2*                                                                                            3.8                 18.6                          Regional            NA                              NA
  10                                          C                                             F                                               *TSC2*                                                                                            1.7                 NA                            NA                  NA                              NA
  11                                          C                                             M                                               ND                                                                                                3.9                 18.2                          Regional            NA                              NA
  12                                          C                                             M                                               NMI                                                                                               5.6                 24.7                          NA                  NA                              NA
  13                                          C                                             M                                               *TSC1*                                                                                            0.8                 0.8                           Bilateral           NA                              NA
  14                                          AA                                            F                                               *TSC2*                                                                                            0.6                 NA                            Focal               11.1                            Focal
  15                                          C                                             F                                               *TSC2*                                                                                            1.5                 NA                            Regional            2.2                             Focal
  16[e](#epi16379-note-0008){ref-type="fn"}   C                                             M                                               *TSC2*                                                                                            0.7                 0.7                           Regional            12.1                            Focal
  17                                          C                                             M                                               *TSC2*                                                                                            1.2                 1.2                           Focal               6.1                             Focal + ES
  18                                          C                                             M                                               *TSC2*                                                                                            1.1                 4.0                           Regional            6.9                             ES
  19[e](#epi16379-note-0008){ref-type="fn"}   C                                             M                                               *TSC2*                                                                                            0.7                 0.7                           Bilateral           1.1                             ES + Focal
  20                                          C                                             M                                               *TSC2*                                                                                            1.2                 6.1                           Bilateral           6.3                             ES
  21                                          C                                             M                                               *TSC2*                                                                                            1.3                 1.3                           Bilateral           1.3                             Focal
  22                                          A                                             M                                               *TSC2*                                                                                            1.4                 1.4                           Focal               3.9                             Focal
  23                                          C                                             M                                               *TSC2*                                                                                            4.4                 4.4                           Bilateral           6.1                             ES
  24                                          H                                             F                                               *TSC2*                                                                                            6.2                 6.2                           Focal               20.1                            Focal
  25                                          AI                                            M                                               *TSC2*                                                                                            1.6                 1.6                           Bilateral           3.4                             Focal
  26                                          C                                             F                                               *TSC2*                                                                                            1.6                 NA                            Focal               3.5                             ES + Focal
  27                                          C                                             F                                               *TSC2*                                                                                            2.6                 4.2                           Bilateral           6.1                             Focal + ES
  28                                          C                                             M                                               *TSC2*                                                                                            4.0                 4.0                           Regional            4.8                             ES
  29                                          C                                             F                                               *TSC1*                                                                                            2.7                 NA                            Bilateral           5.5                             GTC + Focal
  30[e](#epi16379-note-0008){ref-type="fn"}   C                                             M                                               *TSC2*                                                                                            0.7                 0.7                           Focal               11.3                            Focal
  31                                          C                                             F                                               *TSC2*                                                                                            3.9                 4.2                           Bilateral           5.8                             ES
  32                                          C                                             F                                               *TSC2*                                                                                            2.4                 4.5                           Bilateral           5.9                             ES + GTC
  33                                          C                                             M                                               *TSC2*                                                                                            6.0                 9.1                           Regional            12.7                            ES
  34                                          C                                             F                                               *TSC1*                                                                                            3.5                 3.5                           Regional            4.6                             ES
  35                                          C                                             F                                               *TSC2*                                                                                            6.6                 6.6                           Regional            8.3                             ES
  36[e](#epi16379-note-0008){ref-type="fn"}   C                                             M                                               ND                                                                                                2.1                 4.4                           Bilateral           15.1                            ES
  37                                          NR                                            F                                               NMI                                                                                               2.3                 3.7                           Focal               11.7                            Focal
  38[e](#epi16379-note-0008){ref-type="fn"}   C                                             F                                               *TSC2*                                                                                            1.0                 1.0                           Bilateral           3.3                             Focal + ES

A, Asian; AA, African American; AI, American Indian; C, Caucasian; H, Hispanic; NR, not reported.

M, male; F, female.

NMI, no mutation identified; ND, not done.

ES, epileptic spasms; GTC, generalized tonic‐clonic; NA, not applicable.

Excluded for pretreatment.

John Wiley & Sons, Ltd

Of the 40 participants, 2 were lost to follow‐up (5%) and 32 were analyzed for both seizure outcome and developmental outcome. The remaining six were pretreated with vigabatrin for electrographic seizures before clinical seizure onset or for IEDs before clinical seizure onset and excluded from analysis.

For the 38 participants, 22 boys and 16 girls were enrolled in this study with a mean age of 82.4 days ± 59.8 days. Genetic testing was performed for the majority of participants (n = 35). Mutations of *TSC1* were identified for 7, *TSC2* mutations for 26, and no mutation identified for 2 participants.

3.2. Video‐EEG findings and seizure outcome {#epi16379-sec-0015}
-------------------------------------------

A total of 268 of 280 anticipated EEG recordings (96%) were acquired on the 38 participants enrolled. A total of 132 visits (49%) were subject to scheduling changes, typically limited to several days outside of the 2‐week window in year 1, and greater variability allowed in year 2, due to more time between visits. The interreader reliability/kappa scores were calculated between the two central readers for five major findings on the EEG, namely IEDs, focal or generalized slowing, focal or generalized attenuation, hypsarrhythmia, and ictal events. It is important to note that less than 5% of the EEG recordings were deemed to show any variation of hypsarrhythmia (modified vs classic hypsarrhythmia). IEDs seen as part of hypsarrhythmia were classified into the category of hypsarrhythmia.

For the 32 participants in the EEG and seizure outcome analysis, 17 showed IEDs on EEG studies performed prior to their clinical seizure onset (true positives), and 3 did not have IEDs on their EEG recordings prior to their clinical seizure onset (false negatives). Throughout the study, seven participants maintained normal EEG studies and never developed clinical seizure (true negatives), and five had IEDs but never had clinical seizures (false positives). The positive predictive value, or how often IEDs can predict subsequent epilepsy, is 77.3%. The negative predictive value, or how often the absence of IEDs predicted no subsequent epilepsy, is 70%. The sensitivity of detecting IEDs before ensuing epilepsy is 85%. Finally, the specificity of lack of IEDs predicted no epilepsy up to 2 years of age is 58.3%. The age at the first emergence of IEDs averaged 4.5 months ± 4.0 standard deviation (SD), with a median age of 4.0 months for those infants who went on to develop seizures. The age at seizure onset of any type, for those with antecedent epileptiform activity, averaged 7.5 months ± 4.4 SD, with a median age of 6.0 months. The interval between the onset of IEDs and clinical epilepsy onset averaged 3.6 months ± 3.4 SD.

Twelve of the 32 participants (37.5%) remained seizure‐free throughout the study with no antiepileptic drug (AED) treatment; seven maintained normal EEG findings and never developed seizures, and five had evidence of interictal epileptiform activity on only one EEG by the time the study was completed at age 24 months. Twenty of the 32 infants developed seizures (62.5%). The seizure types consisted of focal seizures in seven (35%), epileptic spasms in six (30%), focal seizures and generalized tonic‐clonic seizures in one (5%), and focal seizures with epileptic spasms in six (30%). No other seizure types were reported.

After seizure onset, 76% were treated within 2 days, and 90% within 1 week of seizure onset. At the completion of the study at 24 months, 8 of the 20 (40%) continued to have clinical seizures, and 9 (45%) were reported to be seizure‐free, defined as seizure freedom of 3 months or longer. Only one of three participants (15%) who was a false negative (normal EEG but developed clinical seizures) was seizure‐free at 24 months. Two of the three underwent epilepsy surgery after their seizure onset: one is seizure‐free at 24 months and the other had reduction in their seizure severity but continued to have occasional breakthrough seizures requiring emergency rescue medication.

For the six infants who were pretreated with vigabatrin before the onset of clinical seizures, only one infant did not go on to develop clinical seizures. Of the five who did have seizures while on vigabatrin, three had focal seizures as their sole seizure type, one had focal seizures then epileptic spasms, and one had an unclassified seizure type. Two of the five had been seizure‐free for 3 months or longer at the time of study completion of 24 months, and three continued to have seizures. These six participants were not included in the developmental outcome analysis because of the protocol deviation during the study.

3.3. Developmental outcome {#epi16379-sec-0016}
--------------------------

For the Mullen Scales of Early Learning composite scores and Vineland‐II scores obtained at the three time points of 6, 12, and 24 months of age (Figure [1](#epi16379-fig-0001){ref-type="fig"}), the results were analyzed among three subgroups of the following: (a) true positive infants with IEDs on EEG prior to onset of clinically refractory epilepsy (ongoing seizures despite AED treatment, n = 8); (b) true positive infants with IEDs on EEG prior to onset of clinically controlled epilepsy (control for at least 3 months or longer with AED treatment, n = 9); and (c) infants who never had seizures, regardless of their EEG findings. This third group included true negative infants (no IEDs in any EEG and no seizures, n = 7) and false‐positive infants (IEDs in any EEG but no subsequent seizures, n = 5). The rationale for analyzing the five false‐positive patients together with the true negative patients is that this study was observational in nature, and no epilepsy treatment was started in patients with an abnormal EEG only. Moreover, these patients had only a single abnormal EEG.

![Results of developmental assessments (Vineland‐II and Mullen Scales of Early Learning Composite scores) from linear mixed models evaluating longitudinal developmental outcomes. Developmental assessments were given at 6, 12, and 24 months of age. (TP‐sz‐free, True‐positive seizure free; TP‐sz, True‐positive seizure; No‐sz, No seizure). Vineland‐II Standard Scores: \<70 Well Below Average, 70‐84 Below Average, 85‐115 Average range, 116‐130 Above Average, \>130 Well Above Average. Mullen Composite standard scores: 49‐70 very low, 71‐84 below average, 85‐115 average, 116‐129 above average, 130‐155 very high](EPI-60-2428-g001){#epi16379-fig-0001}

Known variants in *TSC1* and *TSC2* genes did not statistically influence the Vineland‐II or Mullen Scales of Early Learning; therefore, they were not retained in the final model. The result of the linear mixed models showed significant overall differences between the three classifications for the Mullen (*P* = .002) and the Vineland‐II (*P* = .04). Overall changes (all groups combined) over the three time points were not statistically significant for either scale. The group‐by‐time interaction was significant for the Vineland‐II score (*P* = .04) but not significant for the Mullen composite score. Follow‐up analyses showed that of these three subgroups, the group with refractory epilepsy scored progressively lower with advancing age on both the Vineland‐II (*P* = .018) and the Mullen Scale of Early Learning (*P* = .03). There were no differences between patients who never developed seizures and those who gained seizure freedom.

4. DISCUSSION {#epi16379-sec-0017}
=============

This prospective multicenter observational study of infants with TSC provides several important findings: interictal spikes on serial scalp video‐EEG studies identified correctly nearly 80% of infants who subsequently developed epilepsy. Furthermore, antecedent spikes predicted the impending seizure onset on average about 3.5 months before seizure onset. For these initially seizure‐naive infants, this critical interval between the first appearance of IEDs and the subsequent seizure onset presents a window of opportunity for a disease‐modifying antiepileptogenic therapy. Clinical trials are needed to determine if such interventions can alter the overall course of epilepsy in TSC.

It is interesting to note that for the five infants who had IEDs but never developed seizures, all five had IEDs on a single EEG only, which resolved on subsequent EEG studies. This differed from the 17 infants who had persistent IEDs on serial EEG recordings before their seizure onset. Why this cortical irritability is present only transiently and culminated in seizure onset in some TSC infants but not others is not clear and deserves further attention and investigation. One possible concern is that the identification of subtle sharps or spikes was not accurate. The kappa scores between the EEG readers were 0.54 for IEDs and 0.56 for ictal events. Only IEDs predicted and correlated with eventual seizure outcome. Although the kappa score is lower than what we had strived for, there are examples in the literature citing the difficulty in obtaining higher interrater kappa score on EEG studies. Perhaps the best example would be Hussain et al (2015), in which EEG recordings from an age group of infants similar to this study posed difficulty in assessing hypsarrhythmia. More specifically, raters from different institutions in the Hussain et al[10](#epi16379-bib-0010){ref-type="ref"} study had a kappa score of 0.52 in assessing a single focus of IEDs, similar to our interinstitutional kappa score in this study.

The epilepsy incidence rate of 62.5% from this prospective cohort is consistent with, although somewhat lower than, the 77.9% epilepsy incidence rate by 24 months of age in a larger retrospective study, which may have an inherent bias given that the patients were seen at an epilepsy center or the removal of TSC patients presenting with epilepsy from our cohort.[4](#epi16379-bib-0004){ref-type="ref"} The 30% incidence of epileptic spasms in our subjects is consistent with that of the large retrospective series.[4](#epi16379-bib-0004){ref-type="ref"} Focal seizures in 35% of our cohort by 2 years of age is difficult to compare to the nearly 87% of patients with focal seizures in all age groups,[4](#epi16379-bib-0004){ref-type="ref"} not limited to the first 2 years of life.

The refractory seizure rate of 40%, however, is lower than the 64% refractory epilepsy rate reported in one large retrospective series.[4](#epi16379-bib-0004){ref-type="ref"} Potential explanation of the lower refractory epilepsy rates here include higher rates of referral to epilepsy centers of patients with difficult to control epilepsy in retrospective studies, exclusion of early onset epilepsy patients from the study, and longer‐term follow‐up in the retrospective study cohorts. Long term it will be interesting to see if early recognition and prompt treatment of seizures in TSC alter long‐term seizure outcomes.

Perhaps, as or more important than epilepsy outcome, the developmental outcome among the subgroups of TSC infants in this study demonstrates that the progressive decline in developmental assessments is clearly linked to the persistence of seizures. Our data suggest that there is a specific association between severity of epilepsy and comorbid conditions, including developmental delay, reported previously in retrospective and prospective series.[4](#epi16379-bib-0004){ref-type="ref"}, [11](#epi16379-bib-0011){ref-type="ref"}, [12](#epi16379-bib-0012){ref-type="ref"}, [13](#epi16379-bib-0013){ref-type="ref"} We recognize that this study did not incorporate the neuroimaging findings for this cohort, which also may be a contributing factor to the cognitive decline in some of the participants.

Our study demonstrates that early TSC diagnosis and serial EEG monitoring of infants can identify those TSC infants at highest risk for developing seizures months before clinical seizures will begin, but it does not clarify the role of early therapy in long‐term outcome. Our clinically available EEG biomarker, through risk‐stratification, can limit vigabatrin exposure to only those at high risk for the development of epilepsy. It could be used in trials focused on preventative therapy in TSC, like the EPISTOP completed in August 2018. This randomized open‐label trial of preemptive vigabatrin in TSC reported a delay in onset of clinical seizures and a reduction of drug‐resistant epilepsy.[14](#epi16379-bib-0014){ref-type="ref"} Further study is needed and studies like the PREVeNT trial (NCT02849457) and final results from EPISTOP (<http://www.EPISTOP.eu>) will aid in determining if early interventions prior to the development of epilepsy with antiseizure medications such as vigabatrin will be useful to prevent epilepsy, refractory epilepsy, and cognitive impairment in children with epileptiform EEGs.

 {#epi16379-sec-0020}
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